<circle stroke="#1e77f9" class="srdi68r9" cx="25" cy="25" r="20" fill="none" stroke-width="5">

Roche says set to resume shipments of Sarepta’s Elevidys outside U.S.

PremiumThe Fly

12h ago

Trump administration mulls charging patent holders 1%-5% fee, WSJ reports

PremiumThe Fly

1d ago

AZN

BMY

PremiumThe Fly

Roche price target raised to CHF 230 from CHF 220 at JPMorgan

1d ago

Genentech to present new data from Alzheimer’s development portfolio

PremiumThe Fly

2d ago

PremiumThe FlyRoche plans to test if new medicine can prevent AD symptoms, Bloomberg says

2d ago

Roche says will work with EMA on path forward for Elevidys

The Fly

Roche says will work with EMA on path forward for Elevidys

5d ago

European Union committee recommends against Sarepta’s Elevidys

The Fly

European Union committee recommends against Sarepta’s Elevidys

5d ago

Brazil suspends sales of Sarepta’s Elevidys after deaths

PremiumThe Fly

5d ago

Roche Reports Strong Sales Growth in H1 2025

PremiumCompany Announcements

5d ago

PremiumThe Fly

Sarepta price target lowered to $35 from $40 at Jefferies

6d ago

Roche says Brazilian death unrelated to Elevidys, Bloomberg reports

PremiumThe Fly

6d ago

PremiumThe FlyRoche says Elevidys benefit-risk in ambulatory patients remains positive

6d ago

H.C. Wainwright sees rejection for Sarepta in Europe tomorrow

The Fly

H.C. Wainwright sees rejection for Sarepta in Europe tomorrow

6d ago

Roche Holding AG: Hold Rating Amid Mixed Financial Signals and Strategic Challenges

Ratings

Roche Holding AG: Hold Rating Amid Mixed Financial Signals and Strategic Challenges

6d ago

Roche reports 1H group sales CHF 30.9B vs. CHF 29.8B last year

PremiumThe Fly

6d ago

Roche sees FY25 core EPS growing in high single digit range

PremiumThe Fly

6d ago

Roche receives CE Mark for Elecsys pTau181

PremiumThe Fly

7d ago

LLY

Roche pauses shipments of Elevidys outside the U.S., Bloomberg says

PremiumThe Fly

7d ago

PremiumThe FlyRoche announces European Commission approved Itovebi

7d ago

Roche announces ALIENTO trial meets, ARNASA study misses primary endpoint

The Fly

Roche announces ALIENTO trial meets, ARNASA study misses primary endpoint

9d ago

Genetech: STARGLO data does not provide sufficient evidence for DLBCL indication

The Fly

Genetech: STARGLO data does not provide sufficient evidence for DLBCL indication

11d ago